In today’s briefing:
- HealthEquity Inc.: The Product & Service Innovation & Other Major Drivers
- Pre-IPO HealthyWay (PHIP Updates) – Some Points Worth the Attention
- Paras Healthcare Pre-IPO: Increasing Efficiency but Patients Are Spending Less
HealthEquity Inc.: The Product & Service Innovation & Other Major Drivers
- HealthEquity’s third-quarter fiscal 2025 performance and strategic positioning provide insights into potential investment considerations.
- The company reported a 21% increase in revenue year-over-year, indicating robust growth across key metrics, including adjusted EBITDA and Health Savings Account (HSA) assets.
- Notably, HSA assets grew by 33%, and the number of HSA members increased by 15%, demonstrating positive momentum and expansion within their core offering.
Pre-IPO HealthyWay (PHIP Updates) – Some Points Worth the Attention
- The two core businesses is corporate and digital marketing services (2B business) and health and medical services (2C business),the synergy of which can form a virtuous cycle within the platform.
- The key performance driver for HealthWay is 2B business, but the pain point is 2C business, which is hard to scale up. Actually, HealthyWay’s growth momentum has slowed down significantly.
- After completing the final round of financing, HealthyWay’s valuation reached RMB4.1 billion. We think its valuation could be higher than ClouDr but lower than JD Health and Alibaba Health.
Paras Healthcare Pre-IPO: Increasing Efficiency but Patients Are Spending Less
- Paras Healthcare Limited (0490145D IN) is looking to raise up to US$180m in its upcoming India IPO.
- It is the fifth largest healthcare provider in India with a core focus on providing affordable and quality, specialized tertiary medical care in Tier 2 and 3 cities.
- In this note, we look at the firm’s past performance.